|
7 Companies |
|
8 Products |
|
8 Products |
|
0 Mechanisms of Action |
|
0 Trials |
|
12 News |
|
- | imatinib / Generic mfg.
Trial completion: Imatinib (Gleevec(Registered Trademark)) to Treat Chronic Myelomonocytic Leukemia and Atypical Chronic Myelogenous Leukemia (clinicaltrials.gov) - Jun 30, 2017
P2, N=7, Completed, Sponsor: National Heart, Lung, and Blood Institute (NHLBI)
Active, not recruiting --> Completed
- ||| Biomarker, Trial completion, Trial primary completion date: Studying Biomarker Expression in Samples From Patients With Down Syndrome and Acute Myeloid Leukemia or Other Transient Myeloproliferative Disorder (clinicaltrials.gov) - May 19, 2016
P=N/A, N=60, Completed, Sponsor: Children's Oncology Group
Active, not recruiting --> Completed Active, not recruiting --> Completed | Trial primary completion date: Jan 2100 --> May 2016
- Orencia (abatacept) / BMS
Preclinical, Enrollment change, Trial withdrawal: Effect on Orencia (Abatacept) on the Apoptosis of T Cells, B Cells and APC Cells in Rheumatoid Arthritis (clinicaltrials.gov) - May 12, 2016
P4, N=0, Withdrawn, Sponsor: University of California, Los Angeles
Active, not recruiting --> Completed | Trial primary completion date: Jan 2100 --> May 2016 N=24 --> 0 | Not yet recruiting --> Withdrawn
- | Trial completion, Retrospective data, Enrollment change, Trial primary completion date: WBCD: Data Collection of Routine Clinical Use With the Spectra Optia® Apheresis System for White Blood Cell Depletion (clinicaltrials.gov) - May 8, 2015
P=N/A, N=43, Completed, Sponsor: Terumo BCT
N=24 --> 0 | Not yet recruiting --> Withdrawn Active, not recruiting --> Completed | N=59 --> 43 | Trial primary completion date: Nov 2014 --> Apr 2015
- ||| Retrospective data: WBCD: Data Collection of Routine Clinical Use With the Spectra Optia® Apheresis System for White Blood Cell Depletion (clinicaltrials.gov) - Nov 28, 2014
P=N/A, N=59, Active, not recruiting, Sponsor: Terumo BCT
- Trial completion: Low-Dose or High-Dose Conditioning Followed by Peripheral Blood Stem Cell Transplant in Treating Patients With Myelodysplastic Syndrome or Acute Myelogenous Leukemia (clinicaltrials.gov) - Oct 31, 2014
P3, N=25, Completed, Sponsor: Fred Hutchinson Cancer Research Center
Active, not recruiting --> Completed | N=59 --> 43 | Trial primary completion date: Nov 2014 --> Apr 2015 Active, not recruiting --> Completed
- MK-2206 / Merck (MSD)
Enrollment change: MK2206 in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Leukemia (clinicaltrials.gov) - Apr 27, 2014
P1, N=45, Completed, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed N=96 --> 45
- MK-2206 / Merck (MSD)
Trial completion: MK2206 in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Leukemia (clinicaltrials.gov) - Sep 26, 2013
P1, N=45, Completed, Sponsor: National Cancer Institute (NCI)
N=96 --> 45 Active, not recruiting --> Completed
- cytarabine / Generic mfg.
Enrollment change: Low-Dose Cytarabine in Treating Infants With Down Syndrome and Transient Myeloproliferative Disorder (clinicaltrials.gov) - Aug 21, 2013
P3, N=0, Withdrawn, Sponsor: Children's Oncology Group
Active, not recruiting --> Completed N=180 --> 0
- Enrollment change: Low-Dose or High-Dose Conditioning Followed by Peripheral Blood Stem Cell Transplant in Treating Patients With Myelodysplastic Syndrome or Acute Myelogenous Leukemia (clinicaltrials.gov) - Aug 20, 2013
P3, N=25, Active, not recruiting, Sponsor: Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
N=180 --> 0 N=280 --> 25
- | Orencia (abatacept) / BMS
New P4 trial, Preclinical: Effect on Orencia (Abatacept) on the Apoptosis of T Cells, B Cells and APC Cells in Rheumatoid Arthritis (clinicaltrials.gov) - Oct 23, 2012
P4, N=24, Not yet recruiting, Sponsor: University of California, Los Angeles
- || Biomarker, Enrollment closed: Studying Biomarker Expression in Samples From Patients With Down Syndrome and Acute Myeloid Leukemia or Other Transient Myeloproliferative Disorder (clinicaltrials.gov) - Feb 13, 2012
P=N/A, N=60, Active, not recruiting, Sponsor: Children's Oncology Group
N=280 --> 25 Not yet recruiting --> Active, not recruiting